GACI First Investment Company - Publication of Pricing Supplements
THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW
28 January 2025
The following pricing supplements (together, the "Pricing Supplements") are available for viewing:
The pricing supplement in relation to the issue of U.S.2,400,000,000 5.250 per cent. Notes due 2030 by GACI First Investment Company (the "Issuer") under its Guaranteed Euro Medium Term Note Programme (the "Programme"). A copy of such pricing supplement can be viewed at:
http://www.rns-pdf.londonstockexchange.com/rns/0059V_1-2025-1-28.pdf
The pricing supplement in relation to the issue of U.S.1,600,000,000 5.625 per cent. Notes due 2034 by the Issuer under the Programme. A copy of such pricing supplement can be viewed at:
http://www.rns-pdf.londonstockexchange.com/rns/0059V_2-2025-1-28.pdf
For further information, please contact: investors@pif.gov.sa
DISCLAIMER - INTENDED ADDRESSEES
The Pricing Supplements must be read in conjunction with the offering circular dated 3 September 2024 as supplemented by the supplemental offering circular dated 22 January 2025, which together constitute an offering circular (the "Offering Circular").
Please note that the information contained in the Pricing Supplements and the Offering Circular may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Pricing Supplements and/or Offering Circular) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Pricing Supplements and/or Offering Circular is not addressed. Prior to relying on the information contained in the Offering Circular you must ascertain from the Pricing Supplements and Offering Circular whether or not you are part of the intended addressees of the information contained therein.
The Pricing Supplements do not constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction. The securities referred to in the Pricing Supplements have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act, and the rules and regulations thereunder. The Issuer does not intend to register the securities referred to in the Pricing Supplements in the United States or to conduct a public offering of the securities referred to in the Pricing Supplements in the United States or elsewhere.
Your right to access this service is conditional upon complying with the above requirement.
No offer or invitation to acquire any securities is being made pursuant to this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
